HDL increasing drugs

systematic review meta-analysis network meta-analysis

Select cardiovascular prevention All type of patient       CETP inhibitorfibratesniacinniacin (on top statin) bezafibratefenofibrateanacetrapibclofibrateetofibrategemfibrozilniacintorcetrapib vs placebovs placebo or controlvs ezetimibe       cerebral vascular diseasetype 2 diabetes

Filter

Group by Group by... nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition MA  in first nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in second nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in third	Description Synopsis Comparison Treatments Patients Characteristics Method Risk of bias References None Tools Indexation					Results Global trial result Main results All results All result tag NCT results	All cause death (30)Coronary event (26)cardiac death (20)Coronary death (19)non cardiovascular death (17)cardiovascular events (15)Non fatal MI (13)stroke (fatal and non fatal) (12)Cardiovascular death (9)Death from cancer (6)Coronary revascularization (4)cardiovascular events including revascularization (3)Coronary death and non fatal MI (2)Venous thromboembolism (2)MACE (2)Non fatal stroke (2)Myopathy (1)Rhabdomyolysis (1)Adverse events (1)new-onset diabetes (1)Cancer (1) Options Numeric bar chart forest plot medians
Trial	Studied trt	Control trt	patients	tags	ROB	Trial result	All cause death	Coronary event
cardiovascular prevention
anacetrapib
REALIZE, 2015      NCT	anacetrapib	placebo			Low risk of bias	negative
DEFINE, 2010    NCT	anacetrapib	placebo			Exploratory	negative
bezafibrate
BECAIT, 1996	bezafibrate	placebo	secondary prevention		Exploratory	suggesting
BIP, 2000	bezafibrate	placebo	secondary prevention		Low risk of bias	negative
SENDCAP, 1998	bezafibrate	placebo		type 2 diabetes	Exploratory	suggesting
LEADER, 2002	bezafibrate	placebo			Low risk of bias	negative
clofibrate
WHO clofibrate, 1978	clofibrate	placebo			Low risk of bias	suggesting
CDP Clofibrate, 1975	clofibrate	placebo			Low risk of bias	suggesting
Hanefeld, 1991	clofibrate	placebo		type 2 diabetes	Low risk of bias	negative
Scottish, 1971	clofibrate	placebo			Low risk of bias	negative
Newcastle, 1971	clofibrate	placebo			Low risk of bias	suggesting
Harrold, 1969	clofibrate	placebo		type 2 diabetes	Low risk of bias	-
Begg, 1971	clofibrate	placebo	secondary prevention		Exploratory	negative
Acheson, 1972	clofibrate	placebo	secondary prevention	cerebral vascular disease	Exploratory	-
VA Neurology Section, 1974	clofibrate	placebo			Low risk of bias	-
Cullen, 1974	clofibrate	placebo			Low risk of bias	-
etofibrate
Emmerich, 2009	etofibrate	placebo	diabetic	type 2 diabetes	Exploratory	-
fenofibrate
DAIS, 2001	fenofibrate	placebo	diabetic	type 2 diabetes	Exploratory	negative
FIELD, 2005	fenofibrate	placebo	diabetic	type 2 diabetes	Low risk of bias	suggesting
ACCORD lipid, 2010    NCT	fenofibrate	placebo (on top simvastatine)	diabetic patients		Low risk of bias	negative
gemfibrozil
LOCAT, 1997	gemfibrozil	placebo			Exploratory	negative
Helsinki (HHS), 1987	gemfibrozil	placebo			Low risk of bias	suggesting
VA-HIT, 1999      NCT	gemfibrozil	placebo			Low risk of bias	suggesting
HHS (Frick)(secondary prev subgroup), 1993	gemfibrozil	placebo			Exploratory	negative
niacin
VA drugs, 1968	niacin	control			Low risk of bias	negative
CDP niacin, 1975	niacin	placebo			Low risk of bias	suggesting
AIM-HIGH, 2011      NCT	niacin	placebo (on top statin)			Low risk of bias	negative
HPS 2-Thrive      NCT	niacin	placebo (on top statin)			Low risk of bias	negative
Oxford Niaspan Study, 2009    NCT	niacin	placebo (on top statin)			Exploratory	-
ARBITER 2, 2009	niacin	placebo (on top statin)			Exploratory	negative
HATS, 2001	niacin	placebo (on top statin)			Low risk of bias	negative
ARBITER 6-HALTS (niacin vs ezetimibe), 2009        NCT	niacin	ezetimibe			Exploratory	suggesting
torcetrapib
RADIANCE 1, 2007      NCT	torcetrapib	placebo			Exploratory	negative
ILLUMINATE, 2007      NCT	torcetrapib	placebo			Low risk of bias	negative
RADIANCE 2, 2007	torcetrapib	placebo			Low risk of bias	-
ILLUSTRATE, 2007      NCT	torcetrapib	placebo			Exploratory	negative